Company Filing History:
Years Active: 2013
Title: Mairi Sime: Innovator in P2X7 Modulation
Introduction
Mairi Sime is a prominent inventor based in Harlow, GB. She has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate P2X7 receptor function. With a total of 2 patents, her work is paving the way for new treatments for various pain-related conditions.
Latest Patents
Mairi Sime's latest patents include innovative compounds designed to act as P2X7 modulators. The first patent focuses on 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives. These compounds are believed to modulate P2X7 receptor function and can antagonize the effects of ATP at the receptor. The invention highlights potential applications in treating inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis, and neurodegenerative disorders. The second patent involves 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives, which share similar therapeutic potential and mechanisms of action.
Career Highlights
Mairi Sime is currently associated with Glaxo Group Limited, where she continues her research and development efforts. Her work is instrumental in advancing the understanding of P2X7 receptor modulation and its implications for pain management.
Collaborations
Mairi has collaborated with notable colleagues, including David Kenneth Dean and Jorge Munoz-Muriedas. These partnerships enhance the innovative potential of her research and contribute to the broader scientific community.
Conclusion
Mairi Sime's contributions to the field of pharmacology through her patents on P2X7 modulators are significant. Her work not only advances scientific knowledge but also holds promise for improving treatment options for various pain-related disorders.